Bcr-Abl Amplification Plays a Major Role in Resistance to Tyrosine Kinase Inhibitors in K-562 Cell Line
DOI:
https://doi.org/10.12775/v10251-012-0054-2Keywords
BCR-ABL amplification, chronic myeloid leukemia, drug resistance, imatinib, tyrosine kinase inhibitors, K-562 cell lineAbstract
An emerging problem in patients with chronic myeloid leukemia (CML) is increasing resistance to tyrosine kinase inhibitors (TKIs). To determine genetic and cellular mechanisms involved in the development of resistance to TKIs, nine imatinib-resistant cell lines were derived from K- 562 cell line followed by testing of drug sensitivity, multidrug resistance proteins and cytogenetic studies. In imatinib-resistant cell lines cross-resistance to daunorubicin, etoposide and cytarabine were observed whereas sensitivity to dasatinib, nilotinib, cyclophpsphamide, bortezomib and busulfan was preserved. Treatment with imatinib decreased PGP and LRP expression, however it did not significantly influence MRP1 expression. Amount of signals in FISH analysis from ABL, BCR and from fusion genes (BCR-ABL or ABL-BCR) was mostly higher in imatinib-resistant cell lines in comparison to parental K-562 cell line. We concluded that BCR-ABL amplification but not cellular sensitivity is the major mechanisms of resistance in K-562 cell line.References
Khamaisie H, Sussan S, Tal M, et al. Oleic acid is the active component in the mushroom Daedalea gibbosa inhibiting Bcr-Abl kinase autophosphorylation activity. Anticancer Res. 2011; 31 (1): 177-183.
Baccarani M, Cortes J, Pane F, et al. Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. J Clin Oncol. 2009; 27 (35):6041-6051. [ http://dx.doi.org/10.1200/JCO.2009.25.0779]
Bixby D, Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am Soc Hematol Educ Program. 2009: 461-476.
Lahaye T, Riehm B, Berger U, et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5- year follow-up. Cancer. 2005; 103 (8): 1659-1669. [ http://dx.doi.org/10.1002/cncr.20922]
Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002; 16 (11): 2190-2196.
Styczynski J, Toporski J, Wysocki M, et al. Fludarabine, treosulfan and etoposide sensitivity and the outcome of hematopoietic stem cell transplantation in childhood acute myeloid leukemia. Anticancer Res. 2007; 27 (3B): 1547-1551.
Gil L, Styczynski J, Dytfeld D, et al. Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia. Anticancer Res. 2007; 27 (6B): 4021-4025.
Sierra JR, Cepero V, Giordano S. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer. 2010; 9: 75. [ http://dx.doi.org/10.1186/1476-4598-9-75]
Suzuki M, Abe A, Imagama S, et al. BCR-ABLindependent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4. Eur J Haematol. 2010; 84 (3): 229-238. [ http://dx.doi.org/10.1111/j.1600-0609.2009.01387.x]
Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003; 101 (2): 473-475. [ http://dx.doi.org/10.1182/blood-2002-05-1451]
O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations and the unsettled problem of Bcr- AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemia. Clin Lymphoma Myeloma. 2007; 7 Suppl 3: 120-130.
O'Hare T, Walters DK, Deininger MW, et al. AMN107: tightening the grip of imatinib. Cancer Cell. 2005; 7 (2): 117-119.
Le Blanc K, Barrett AJ, Schaffer M, et al. Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies. Biol Blood Marrow Transplant. 2009; 15 (9): 1108-1115.
Santos GW. Busulfan (Bu) and cyclophosphamide (Cy) for marrow transplantation. Bone Marrow Transplant. 1989; 4 Suppl 1: 236-239.
Servida F, Soligo D, Delia D, et al. Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I. Leukemia. 2005; 19 (12): 2324-2331. [ http://dx.doi.org/10.1038/sj.leu.2403987]
Albero MP, Vaquer JM, Andreu EJ, et al. Bortezomib decreases Rb phosphorylation and induces caspasedependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells. Oncogene. 2010; 29 (22): 3276-3286.
Mackey JR, Mani RS, Selner M, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 1998; 58 (19): 4349-4357.
Dumontet C, Fabianowska-Majewska K, Mantincic D, et al. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol. 1999; 106 (1): 78-85.
Kano Y, Akutsu M, Tsunoda S, et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood. 2001; 97 (7):1999-2007.
Tipping AJ, Mahon FX, Zafirides G, et al. Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia. 2002; 16 (12): 2349-2357. [ http://dx.doi.org/10.1038/sj.leu.2402775]
Tabrizi R, Mahon FX, Cony Makhoul P, et al. Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571. Leukemia. 2002; 16 (6): 1154-1159.
Paietta E. Classical multidrug resistance in acute myeloid leukaemia. Med Oncol. 1997; 14 (1): 53-60[ http://dx.doi.org/10.1007/BF02990947]
Zong Y, Zhou S, Sorrentino BP. Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia. Leukemia. 2005; 19 (9): 1590-1596.[ http://dx.doi.org/10.1038/sj.leu.2403853]
Ferrao PT, Frost MJ, Siah S-P, et al. Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro. Blood. 2003; 102 (13): 4499-4503.
Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000; 96 (3): 1070-1079.
Mahon F-X, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood. 2003; 101 (6): 2368-2373.
Davies A, Jordanides NE, Giannoudis A, et al. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia. 2009; 23 (11): 1999-2006.
Giannoudis A, Davies A, Lucas CM, et al. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood. 2008; 112 (8): 3348-3354.
le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood. 2000; 95 (5): 1758-1766.
Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABLtransformed hematopoietic cell lines. Blood. 2000 ;95 (11): 3498-3505.
Phan CL, Megat Baharuddin PJ, Chin LP, et al. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia. Cancer Genet Cytogenet. 2008; 180 (1): 60-64. [ http://dx.doi.org/10.1016/j.cancergencyto.2007.09.014]
Quintas-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control. 2009; 16 (2): 122-131.
Downloads
Published
How to Cite
Issue
Section
Stats
Number of views and downloads: 270
Number of citations: 0